Literature DB >> 1991827

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.

C Orskov1, J Jeppesen, S Madsbad, J J Holst.   

Abstract

We investigated the major products of proglucagon (PG) processing in plasma in the fasting state, after intravenous arginine and after an oral glucose load in noninsulin-dependent diabetics (NIDDM) and in weight matched controls using specific radioimmunoassays and analytical gel filtration. In the fasting state the glucagonlike peptide-1 (GLP-1) immunoreactivity was significantly elevated in the NIDDM group compared with the control group. Both after intravenous arginine and after an oral glucose load a rise in the plasma concentrations of all immunoreactive moieties measured was seen. All integrated incremental responses after intravenous arginine were identical in the two groups. After oral glucose the insulin concentrations in plasma were lower and the concentrations of all proglucagon products were higher in the NIDDM group compared to the control group. The gel filtration analysis showed that arginine stimulated the secretion of pancreatic glucagon (PG 33-61), major proglucagon fragment (PG 72-158) and probably GLP-1 (PG 72-107 amide) in both groups, whereas oral glucose stimulated the secretion of glicentin (PG 1-69) and intestinal GLP-1 (PG 78-107 amide), an insulinotropic hormone. The elevated levels of immunoreactive GLP-1 in diabetics in the fasting state were mainly due to an increased concentration of major proglucagon fragment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1991827      PMCID: PMC295092          DOI: 10.1172/JCI115012

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  A sensitive, precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties.

Authors:  J D Albano; R P Ekins; G Maritz; R C Turner
Journal:  Acta Endocrinol (Copenh)       Date:  1972-07

2.  Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences.

Authors:  C Patzelt; E Schiltz
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

3.  Evidence that glicentin contains the entire sequence of glucagon.

Authors:  J J Holst
Journal:  Biochem J       Date:  1980-05-01       Impact factor: 3.857

4.  Exon duplication and divergence in the human preproglucagon gene.

Authors:  G I Bell; R Sanchez-Pescador; P J Laybourn; R C Najarian
Journal:  Nature       Date:  1983 Jul 28-Aug 3       Impact factor: 49.962

5.  Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin.

Authors:  J J Holst
Journal:  Biochem J       Date:  1982-12-01       Impact factor: 3.857

6.  Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.

Authors:  W K Ward; D C Bolgiano; B McKnight; J B Halter; D Porte
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

7.  Studies of pancreatic alpha cell function in normal and diabetic subjects.

Authors:  R H Unger; E Aguilar-Parada; W A Müller; A M Eisentraut
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

8.  Complete sequences of glucagon-like peptide-1 from human and pig small intestine.

Authors:  C Orskov; M Bersani; A H Johnsen; P Højrup; J J Holst
Journal:  J Biol Chem       Date:  1989-08-05       Impact factor: 5.157

9.  Immunoreactive glucagon and insulin C-peptide in man after resection of the pancreas and total pancreatectomy.

Authors:  R Kåresen; B Tronier; S Aune
Journal:  Am J Surg       Date:  1980-08       Impact factor: 2.565

10.  The primary structure of porcine glicentin (proglucagon).

Authors:  L Thim; A J Moody
Journal:  Regul Pept       Date:  1981-05
View more
  98 in total

Review 1.  The role of incretin therapy at different stages of diabetes.

Authors:  Simona Cernea
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 2.  Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes.

Authors:  Xiao C Li; Jia L Zhuo
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

3.  Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes.

Authors:  D H Jensen; K Aaboe; J E Henriksen; A Vølund; J J Holst; S Madsbad; T Krarup
Journal:  Diabetologia       Date:  2012-05       Impact factor: 10.122

4.  Glucagon receptor-mediated extracellular signal-regulated kinase 1/2 phosphorylation in rat mesangial cells: role of protein kinase A and phospholipase C.

Authors:  Xiao C Li; Oscar A Carretero; Yuan Shao; Jia L Zhuo
Journal:  Hypertension       Date:  2006-01-03       Impact factor: 10.190

5.  The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas.

Authors:  J de Heer; J Pedersen; C Orskov; J J Holst
Journal:  Diabetologia       Date:  2007-08-04       Impact factor: 10.122

6.  Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.

Authors:  F K Knop; T Vilsbøll; S Madsbad; J J Holst; T Krarup
Journal:  Diabetologia       Date:  2007-01-16       Impact factor: 10.122

7.  Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric banding.

Authors:  Lotte Usinger; Katrine B Hansen; Viggo B Kristiansen; Steen Larsen; Jens J Holst; Filip K Knop
Journal:  Obes Surg       Date:  2011-05       Impact factor: 4.129

8.  Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass.

Authors:  Carsten Dirksen; Kirstine N Bojsen-Møller; Nils B Jørgensen; Siv H Jacobsen; Viggo B Kristiansen; Lars S Naver; Dorte L Hansen; Dorte Worm; Jens J Holst; Sten Madsbad
Journal:  Diabetologia       Date:  2013-09-19       Impact factor: 10.122

9.  Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.

Authors:  D A D'Alessio; S E Kahn; C R Leusner; J W Ensinck
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

10.  Potent inhibitory effects of transplantable rat glucagonomas and insulinomas on the respective endogenous islet cells are associated with pancreatic apoptosis.

Authors:  N Blume; J Skouv; L I Larsson; J J Holst; O D Madsen
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.